FATE Q1 2025 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-15.4% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$41M-2534.1% margin

Net Income

-$38M-2309.5% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

-12.4%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$35M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$399M

Total Liabilities

$110M

Stockholders' Equity

$288M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	-15.4%
Gross Profit	$2M	-$3M	+156.3%
Operating Income	-$41M	-$51M	+19.2%
Net Income	-$38M	-$48M	+21.6%